RT Book, Section
A1 Chahoud, Jad
A1 Pettaway, Curtis A.
A2 Kantarjian, Hagop M.
A2 Wolff, Robert A.
A2 Rieber, Alyssa G.
SR Print(0)
ID 1190837885
T1 Penile Cancer
T2 The MD Anderson Manual of Medical Oncology, 4e
YR 2022
FD 2022
PB McGraw Hill Education
PP New York, NY
SN 9781260467642
LK accessmedicine.mhmedical.com/content.aspx?aid=1190837885
RD 2024/04/24
AB KEY  CONCEPTSHuman  papillomavirus  infection  appears  to  be  the  possible  cause  of  30%  to  50%  of  penile  cancer  cases  and  appears  to  have  a  prognostic  impact  on  clinical  outcomes  among  patients  with  advanced  disease.Penile-preserving  strategies  should  be  strongly  considered  among  patients  with  low-stage  tumors,  especially  those  limited  to  the  skin  and  the  distal  glans  penis.The  presence  and  the  extent  of  metastasis  to  the  ­inguinal  region  are  the  most  important  prognostic  factors  for  survival  in  patients  with  squamous  cell  carcinoma  of  the  penis.Penile  tumor  T  stage  ≥  T1b,  grade,  lymphovascular  invasion,  and  perineural  invasion  appear  to  be  the  most  important  pathologic  prognostic  factors  for  nodal  spread.  Their  presence  is  used  to  determine  the  need  for  inguinal  staging  procedures  among  patients  with  no  clinically  apparent  inguinal  metastases.Patients  with  bulky  lymphadenopathy  should  undergo  a  multimodal  therapeutic  approach  to  include  neoadjuvant  platinum-based  chemotherapy  with  paclitaxel,  ifosfamide,  and  cisplatin  (TIP)  for  four  cycles  followed  by  consolidation  surgical  lymph  node  dissection  among  responding  patients.Patients  with  relapsed  or  refractory  penile  cancer  to  platinum-based  chemotherapy  have  poor  outcomes  with  current  therapy  modalities,  and  every  effort  should  be  made  to  enroll  these  patients  on  novel  therapeutic  clinical  trials.